A Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects with Refractory Partial Seizures
Latest Information Update: 05 Oct 2021
At a glance
- Drugs Carisbamate (Primary)
- Indications Partial epilepsies
- Focus Therapeutic Use
- Sponsors Janssen-Cilag; SK Life Science
- 01 Aug 2012 Actual initiation date (Feb 2005) added as reported by ClinicalTrials.gov.
- 30 Nov 2007 Results have been reported at AES 2007 (1088724)
- 09 Aug 2007 Status changed from in progress to completed.